We are live on ! Find out more
KNSA icon

Kiniksa Pharmaceuticals

56 hedge funds and large institutions have $295M invested in Kiniksa Pharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 30 increasing their positions, 6 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

513% more capital inflows, than outflows

Capital inflows: $87.8M | Capital outflows: $14.3M

400% more repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 6

80% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 5

10% more funds holding

Funds holding: 51 → 56 (+5)

8.45% more ownership

Funds ownership: 79.1% → 87.56% (+8.5%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

Holders
56
Holders Change
+5
Holders Change %
+9.8%
% of All Funds
1.21%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
9
Increased
30
Reduced
6
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

KNSA Hedge Fund Activity: Q1 2019 in Review

56 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Kiniksa Pharmaceuticals (KNSA) for Q1 2019, worth a combined $295M — down 23% from $385M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new KNSA positions and 5 closed out — a net gain of 4 holders — while 30 added to existing stakes and 6 trimmed.

The largest buyer was ArrowMark Colorado Holdings, opening a new position worth an estimated $31.1M. The largest seller was Cormorant Asset Management, cutting an estimated $10.8M.

  • 56 institutional investors held Kiniksa Pharmaceuticals (KNSA) as of Q1 2019, up from 51 in Q4 2018.
  • Funds reported $295M of Kiniksa Pharmaceuticals stock for Q1 2019, down 23% quarter-over-quarter.
  • 9 funds opened new Kiniksa Pharmaceuticals positions in Q1 2019 and 5 closed out, a net change of +4 holders.
  • The largest Kiniksa Pharmaceuticals buyer in Q1 2019 was ArrowMark Colorado Holdings, an estimated $31.1M added.
  • The largest Kiniksa Pharmaceuticals seller in Q1 2019 was Cormorant Asset Management, an estimated $10.8M sold.

Based on aggregated 13F filings for Q1 2019.